BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Antisense-mediated exon skipping for X-linked Alport syndrome

DISEASE CATEGORY: Renal INDICATION: Renal Exon skipping therapy with an antisense oligonucleotide (ASO) targeting a truncating variant in exon 21 of COL4A5 could treat severe X-linked Alport syndrome. The ASO led to complete exon 21...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting CAPN9 to treat fibrosis

DISEASE CATEGORY: Pulmonary; hepatic; cardiovascular INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis Inhibition of CAPN9 could treat fibrosis by blocking a TGFβ-induced pathway that contributes to fibrosis development. Two tool compound CAPN9 inhibitors decreased TGFβ-induced...
BioCentury | Jan 30, 2019
Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
BioCentury | Jun 13, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice expressing a COL17A1 variant could be used to screen therapies for inflammatory skin diseases. Mice with skin-specific knock-in of a COL17A1 variant lacking the NC16A domain recapitulated the skin inflammation,...
BioCentury | May 23, 2018
Translation in Brief

Toward Tailored Chemo

A group at UCSF is bringing precision medicine to chemotherapies, with a predictive model for drug responses based on single gene deletions. Despite advances in immuno-oncology and targeted therapies, nearly 95% of cancer patients receive...
BioCentury | May 15, 2018
Distillery Techniques

Biomarkers; other

TECHNOLOGY: Gene profiling; computational models A gene profiling-based computational model could identify single-gene deletions as markers of response to therapies for high-grade serous ovarian cancer (HGSOC) patients. The model is generated by transfecting a human...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Other

INDICATION: Genetic disorders Patient sample and mouse studies suggest inhibiting COL6A1 could help treat hyaline fibromatosis syndrome (HFS), which is caused by ANTXR2 mutations. In patients, levels of COL6A1 were higher in HFS skin nodules...
BioCentury | Jan 31, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Choroidal neovascularization (CNV); retinal detachment In vitro and mouse studies suggest the COL4A5 -mimetic peptide AXT107 could help treat CNV and retinal detachment. In vitro , AXT107 bound integrins α v β 3 and α...
BioCentury | Mar 11, 2013
Company News

Oncomatrix sales and marketing update

Oncomatrix launched DMTXinvaScan immunohistochemistry kit worldwide to diagnose and prognose the invasiveness of tumors. The DMTXinvaScan uses a mAb developed by Oncomatrix to detect collagen type XI alpha 1 (COL11A1) gene and its encoded protein,...
Items per page:
1 - 10 of 14